NCT05580562 Phase 3 Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) Study sponsor: Jazz Pharmaceuticals
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2028-06 Estimated
Enrollment · participants 510 Estimated
Source updated 2026-04-16 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
Posted 2026-04-16 · 3 fields changed
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before Measure: Overall survival (OS)
Measure: Progression free survival (PFS) as assessed by using RANO-HGG criteria
+ After Measure: Overall survival (OS)
Planned enrollment increased by 60 participants
− Before 450 participants (planned)
+ After 510 participants (planned)
Primary completion date changed
Check registry source
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial